SEC Filing Summary: Landec Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc.) on January 6, 2021. The filing serves to announce the consolidated financial results for the second quarter of fiscal year 2021. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the cover page text of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are detailed in the provided text. The filing indicates that the Company has issued results for the period, but the magnitude of any changes is not disclosed in this summary document.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific revenue and net income figures for Q2 FY2021 in the attached Exhibit 99.1 press release.
- Confirm the discrepancy between the requested company name (Lifecore Biomedical) and the actual registrant (Landec Corporation).
- Review the full press release for any forward-looking statements or guidance not captured in this 8-K cover page.
- Check the Company's liquidity position and debt levels as detailed in the full financial results.